Orsiro DES Continues to Show Good Results at 3 Years

News

Orsiro DES Continues to Show Good Results at 3 Years

Posted: 02/23/2020
Author:
Brian J. Forrestal, crtonline.com

The Orsiro drug-eluting stent (DES) continues to demonstrate low clinical event rates out to 3 years after implantation, according to late-breaking trial results presented Sunday at Cardiovascular Research Technologies (CRT) 2020 in National Harbor, Maryland.

Most Viewed Pages

One Size Doesn't Fit All: Right-Sizing the SCAI SHOCK Classification to Devices and Techniques

Sirolimus-Eluting Drug-Coated Balloons: Sirolimus Versus PTX What the Data Shows

Higher Lp(a) Levels Linked to Greater Risk of ASCVD, Meta-Analysis Suggests

Abiomed’s Updated Instructions for Certain Impella Pumps Identified as Class I Action: FDA

Live Case | Broadcasting from Tucson Medical Center | Tucson, AZ

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

News

Orsiro DES Continues to Show Good Results at 3 Years

Most Viewed Pages

Explore the Site

Stay Connected